Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 12/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971815 | 1.00 | MBOAT4 (0.70) | MBOAT4HRH3GPR139ITGB3ITGA2B | |
| SCHEMBL19971830 | 0.97 | MBOAT4 (0.76) | MBOAT4HRH3 | |
| SCHEMBL18166165 | 0.97 | MBOAT4 (0.76) | MBOAT4HRH3 | |
| SCHEMBL18166216 | 0.91 | MBOAT4 (0.75) | MBOAT4HRH3ITGB3ITGA2B | |
| SCHEMBL19971856 | 0.91 | MBOAT4 (0.75) | MBOAT4HRH3ITGB3ITGA2B | |
| SCHEMBL18166195 | 0.89 | MBOAT4 (0.64) | MBOAT4HRH3GPR139ITGB3ITGA2B | |
| SCHEMBL19971823 | 0.89 | MBOAT4 (0.64) | MBOAT4HRH3GPR139ITGB3ITGA2B | |
| SCHEMBL18166164 | 0.88 | MBOAT4 (0.81) | MBOAT4HRH3ITGB3ITGA2B | |
| SCHEMBL19971810 | 0.88 | MBOAT4 (0.81) | MBOAT4HRH3ITGB3ITGA2B | |
| SCHEMBL19971805 | 0.85 | MBOAT4 (0.93) | MBOAT4ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885HRH3 4291/4885GPR139 539/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885HRH3 4291/4885GPR139 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.